Tyme Technologies (NASDAQ:TYME) announced its earnings results on Thursday. The company reported ($0.04) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.06) by $0.02, Bloomberg Earnings reports.
Shares of NASDAQ:TYME traded down $0.03 on Friday, hitting $0.98. 571,238 shares of the company were exchanged, compared to its average volume of 464,652. Tyme Technologies has a 1-year low of $0.92 and a 1-year high of $4.64. The stock has a 50 day moving average price of $1.18. The stock has a market cap of $111.95 million, a price-to-earnings ratio of -3.06 and a beta of 0.40.
Separately, Zacks Investment Research downgraded shares of Tyme Technologies from a “buy” rating to a “hold” rating in a research note on Wednesday, April 17th.
Tyme Technologies Company Profile
Tyme Technologies, Inc, a clinical-stage biotechnology company, develops novel cancer therapeutics. It is developing SM-88, a combination therapy based on dysfunctional metyrosine derivatives in Phase II development for metastatic pancreatic cancer and biomarker-recurrent prostate cancer. The company was founded in 2011 and is headquartered in New York, New York.
Featured Article: Leveraged Buyout (LBO)
Receive News & Ratings for Tyme Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyme Technologies and related companies with MarketBeat.com's FREE daily email newsletter.